Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFSF11 | O14788 | 1/20 | 0.38 |
| ▸ | TFPI | P10646 | 4/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 2/20 | 0.36 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155488 | 0.94 | CXCR4 (0.40) | TNFSF11TFPISSTR1SSTR2SSTR4 | |
| SCHEMBL24155481 | 0.93 | TNFSF11 (0.37) | TNFSF11TFPISSTR1SSTR2SSTR4 | |
| SCHEMBL25758456 | 0.81 | ESR1 (0.51) | ESR1 | |
| SCHEMBL24155857 | 0.81 | VDR (0.45) | TNFSF11SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL19545700 | 0.64 | KDM1A (0.69) | SSTR2SSTR4SSTR3SSTR5F11 | |
| SCHEMBL18767060 | 0.60 | TNFSF11 (0.48) | TNFSF11SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL19546167 | 0.60 | KDM1A (0.66) | SSTR2SSTR4SSTR3SSTR5F11 | |
| SCHEMBL31479909 | 0.60 | HSP90AB1 (0.45) | F12CACNA1BKDM1A | |
| SCHEMBL25758263 | 0.60 | TFPI (0.40) | TFPI | |
| SCHEMBL19546166 | 0.60 | KDM1A (0.67) | SSTR2SSTR4SSTR5F11KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VITEK, MICHAEL PETER | 2023-07-06 | — | — | US | disclosed |
| WO-2021263069-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | LI FENGQIAO (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VIP, NPPA, IAPP | TNFSF11 1198/4885TFPI 484/4885SSTR1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.